Vividion Therapeutics Overview

  • Founded
  • 2013
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 125
Employees
  • Latest Deal Type
  • IPO
  • (Cancelled)
  • Latest Deal Amount
  • $100M
Latest Deal Amount
  • Investors
  • 1

Vividion Therapeutics General Information

Description

Developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses. The company's platform applies chemical proteomics to expand the druggable proteome and addresses difficult targets providing transformative treatments, enabling healthcare professionals to eliminate artifacts and create proteome-wide drug interaction maps, for simultaneous target engagement and global selectivity profiling.

Contact Information

Website
www.vividion.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Bayer
Primary Office
  • 5820 Nancy Ridge Drive
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vividion Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. IPO 25-Jun-2021 $100M Cancelled Generating Revenue/Not Profitable
7. Merger/Acquisition 01-Aug-2021 00.00 00000 00.00 Completed Generating Revenue/Not Profitable
6. Later Stage VC (Series C) 01-Feb-2021 00000 00000 00000 Completed Generating Revenue
5. Later Stage VC (Series B) 30-Apr-2019 0000 00000 00000 Completed Generating Revenue
4. Later Stage VC 05-Mar-2018 00000 00000 Completed Generating Revenue
3. Later Stage VC (Series A3) 24-Oct-2017 00.00 000.00 00000 Completed Generating Revenue
2. Later Stage VC (Series A2) 02-Feb-2017 $50M $53.5M 0000 Completed Generating Revenue
1. Later Stage VC (Series A) 11-Apr-2016 $3.5M $3.5M 000 Completed Generating Revenue
To view Vividion Therapeutics’s complete valuation and funding history, request access »

Vividion Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A-3 0,000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A-2 67,333,334 $0.001000 6% $0.6 $0.6 1x $0.6 24.17%
Series A 18,118,465 $0.001000 6% $0.25 $0.25 1x $0.25 6.5%
To view Vividion Therapeutics’s complete cap table history, request access »

Vividion Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnes
Drug Discovery
San Diego, CA
125 As of 2021
00000
00000000

00000000

m veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis au
0000 000000000
Uppsala, Sweden
00 As of 0000
0000000000

0000000

aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea com
0000 000000000
Cambridge, MA
00 As of 0000
00000
00.00 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vividion Therapeutics Competitors (51)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Beactica Therapeutics Venture Capital-Backed Uppsala, Sweden 00 0000000000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
000000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
00000000 Venture Capital-Backed San Carlos, CA 00 00000 00000000000 00000
You’re viewing 5 of 51 competitors. Get the full list »

Vividion Therapeutics Patents

  • 10

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Vividion Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200206201-A1 Cereblon modulators and uses thereof Granted 28-Dec-2018 0000000000
US-10869860-B2 Cereblon modulators and uses thereof Active 28-Dec-2018 0000000000 0
US-20200216507-A1 In vivo engineered cereblon protein Granted 28-Dec-2018 0000000000
EP-3902556-A1 In vivo engineered cereblon protein Pending 28-Dec-2018 00000000000
US-10781239-B2 In vivo engineered cereblon protein Active 28-Dec-2018 C07D211/94 0
To view Vividion Therapeutics’s complete patent history, request access »

Vividion Therapeutics Executive Team (18)

Name Title Board Seat Contact Info
Jeffrey Hatfield Co-Chief Executive Officer and Board Member
Robert Abraham Chief Scientific Officer
Jordon Inloes Scientist
Jin-Quan Yu Ph.D Scientific Co-Founder
Todd Kinsella Ph.D Head of Biology
You’re viewing 5 of 18 executive team members. Get the full list »

Vividion Therapeutics Board Members (12)

Name Representing Role Since
Benjamin Cravatt Ph.D Vividion Therapeutics Co-Founder, Scientific Advisor & Board Member 000 0000
Catherine Friedman Self Board Member 000 0000
Christine Siu Self Board Member 000 0000
Jakob Loven Ph.D Nextech Invest Board Member 000 0000
Jeffrey Hatfield Vividion Therapeutics Co-Chief Executive Officer and Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Vividion Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vividion Therapeutics Former Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
Acuta Capital Partners Hedge Fund Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Altitude Life Science Ventures Venture Capital Minority 000 0000 000000 0
BVF Partners Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 22 investors. Get the full list »

Ready to get started?

Request a free trial